LAG 3 ( CD 223) as a cancer immunotherapy target
University of Pittsburgh · Johns Hopkins University · +2 more institutions
Abstract
Despite the impressive impact of CTLA4 and PD1-PDL1-targeted cancer immunotherapy, a large proportion of patients with many tumor types fail to respond. Consequently, the focus has shifted to targeting alternative inhibitory receptors (IRs) and suppressive mechanisms within the tumor microenvironment. Lymphocyte activation gene-3 (LAG3) (CD223) is the third IR to be targeted in the clinic, consequently garnering considerable interest and scrutiny. LAG3 upregulation is required to control overt activation and prevent the onset of autoimmunity. However, persistent antigen exposure in the tumor microenvironment results in sustained LAG3 expression, contributing to a state of exhaustion manifest in impaired…
Citation impact
- FWCI
- 29.44
- Percentile
- 100%
- References
- 104
Authors
4- LPLawrence P. Andrews
University of Pittsburgh
- AEAriel E. Marciscano
Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center
- CGCharles G. DrakeCorresponding
Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center
- DADario A.A. VignaliCorresponding
University of Pittsburgh, UPMC Hillman Cancer Center
Topics & keywords
- Immunotherapy
- Tumor microenvironment
- Cancer immunotherapy
- Immunology
- Cancer research
- Cancer
- FOXP3
- Ipilimumab
- Good health and well-being